Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of August 2026. The report details a material amendment to a Securities Purchase Agreement entered into on July 3, 2026, with an institutional investor for the issuance of pre-paid purchases of Class A ordinary shares.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data disclosed relates to the capital transaction:
- Aggregate Principal Amount: Up to $31,500,000 (before a $1,500,000 original issue discount).
- Original Floor Price: $0.20 per share.
- Adjusted Floor Price (Post-Consolidation): $16.00 per share following a 1-for-80 share consolidation on August 10, 2026.
- Revised Floor Price (Post-Amendment): $0.20 per share.
Material Changes
The filing reports a significant change in the terms of the pre-existing Securities Purchase Agreement:
- Share Consolidation Impact: A 1-for-80 share consolidation on August 10, 2026, automatically adjusted the purchase floor price from $0.20 to $16.00 per share.
- Amendment No. 1: On August 27, 2026, the Company and the Investor executed an amendment to reduce the floor price back to $0.20 per share, effectively reversing the price impact of the consolidation for this specific transaction.
- Regulatory Filing: The Company filed Amendment No. 1 to its registration statement on Form F-3 in connection with this change.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or general risk factors. The document includes a standard disclaimer stating that the report does not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction where such action would be unlawful without registration.
Investor Verification Checklist
- Verify the final terms of the pre-paid purchase agreement in Exhibit 10.1 (Amendment No. 1).
- Confirm the impact of the 1-for-80 share consolidation on the Company's total outstanding share count and market capitalization.
- Review the status of the Form F-3 registration statement amendment to ensure the offering remains compliant.
- Assess the liquidity implications of the $31.5 million principal amount versus the $1.5 million original issue discount.